Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an ...

New research now suggests that B cells avoid gambling away good mutations by strategically banking successful ones. As described in Nature, successful high-affinity B cells can proliferate under ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 healthcare workers in Catalonia who were followed during three years. The ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

A super-resolution microscopy technique offers an unparalleled glimpse into how monoclonal antibodies bind to their targets ...

Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and ...

An LT-scFv antibody fragment specific for sheep red blood cells was incorporated into the membrane of the Daudi B cell line. Cells were washed and subsequently mixed with sheep red blood cells in ...

Wyatt McDonnell of Infinimmune shares insight on human-first models and what the FDA's policy shift means for biotech R&D.